VEGFA and glioblastoma: Pre-treatment with anti-VEGF-A antibodies resulted in an upregulation of MMP-2 expression in human U251 glioblastoma multiforme (GBM) xenografts and significantly enhanced the oncolytic effects of a subsequently administered conditionally replicating adenovirus (CRAd-S-pk7) (66).